Spero Therapeutics (SPRO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$48.6 million.
- Spero Therapeutics' Enterprise Value rose 3627.47% to -$48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.6 million, marking a year-over-year increase of 3627.47%. This contributed to the annual value of -$52.9 million for FY2024, which is 3071.28% up from last year.
- As of Q3 2025, Spero Therapeutics' Enterprise Value stood at -$48.6 million, which was up 3627.47% from -$31.2 million recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Enterprise Value registered a high of -$31.2 million during Q2 2025, and its lowest value of -$146.4 million during Q4 2021.
- Over the past 5 years, Spero Therapeutics' median Enterprise Value value was -$77.7 million (recorded in 2023), while the average stood at -$82.1 million.
- In the last 5 years, Spero Therapeutics' Enterprise Value skyrocketed by 5912.56% in 2022 and then tumbled by 8599.1% in 2023.
- Over the past 5 years, Spero Therapeutics' Enterprise Value (Quarter) stood at -$146.4 million in 2021, then increased by 25.47% to -$109.1 million in 2022, then soared by 30.04% to -$76.3 million in 2023, then surged by 30.71% to -$52.9 million in 2024, then rose by 8.08% to -$48.6 million in 2025.
- Its Enterprise Value stands at -$48.6 million for Q3 2025, versus -$31.2 million for Q2 2025 and -$48.9 million for Q1 2025.